Business
Inaphaea Deal Extension With Dominion
Inaphaea Deal Extension With Dominion.
About this update from Valirx Plc
[{"type":"text","content":"\n\n \nValiRx PLC\n(\"ValiRx\" or the \"Company\")\n \nInaphaea Deal Extension With Dominion\nLondon, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to provide the following update on the commercial activity of its wholly owned subsidiary Inaphaea BioLabs (\"Inaphaea\").\nInaphaea is pleased to announce that it has signed an extension to the evaluation and commercial use agreement with UK based Dominion Biotech Ltd (\"Dominion\") announced on 30 April 2025. Under the extension, Inaphaea will share access to results from a proprietary screen of approximately 3000 FDA approved drugs (\"3k Screen\") generated in a panel of Patient Derived Cells. The drugs are approved for non-cancer applications and Dominion will mine the data for potential cancer applications, carrying out routine analysis to validate the most promising candidates at its own expense; the parties will agree and share any additional in-depth studies if required. The results of the analysis will be jointly owned and both parties will share equally all costs associated with filing, prosecution and maintenance of any arising patents for any repurposed drugs.\nThe parties will work together to commercialise any new assets either to the owner of the original drug compounds or alternative companies interested in the repurposed assets. Both companies will be free to pursue further research and development projects based on the findings. All revenues generated from this arrangement shall be equally shared after directly attributable costs.\n \nMark Eccleston, CEO of ValiRx commented \"This is an excellent opportunity to unlock additional value from existing data sets acquired with our biobank. We believe there could be significant untapped potential for drug repurposing within this data set which can be realised at a minimal cost by working with our new partner, Dominion. Whilst ValiRx remains committed to its model of evaluation and in-licensing of novel assets, we will leverage all potential value from our assets, including our extensive data sets, particularly where we can achieve some quick wins from established drugs with validated safety profiles. We are pleased to be able to extend our initial agreement with Dominion and look forward to further opportunities to build ...